기본 정보
- 표준 SMILES
Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1- InChIKey
IEJXVRYNEISIKR-UHFFFAOYSA-N- 분자식
- C9H10Cl2N4
- 평균 분자량
- 245.11 g/mol
- 단동위원소 질량
- 244.02825168
개요
Apraclonidine is an imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group. It has a role as a diagnostic agent, a beta-adrenergic agonist, an alpha-adrenergic agonist, an antiglaucoma drug and an ophthalmology drug. It is a dichlorobenzene, a member of guanidines and a member of imidazolines. It is a conjugate base of an apraclonidine(1+).
이름 및 식별자
- 우선 이름
- Apraclonidine
- IUPAC
- 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
- 영어명
- Apraclonidine
- 분자식
- C9H10Cl2N4
- 분자량
- 245.11
이름 및 동의어
이름 더 보기
데이터베이스 식별자
- CAS
66711-21-5- PubChem CID
- 2216
- DTXSID
DTXSID1048415- ChEMBL
CHEMBL647- ChEBI
CHEBI:2788- UNII
- 843CEN85DI
- EC Number
- 636-293-2
- Nikkaji
- J247.956G
물성
구조 계산 물성
- XLogP
- 1.3
- 극성 표면적
- 62.4 Ų
- 수소 결합 공여자 수
- 3
- 수소 결합 수용자 수
- 2
- 회전 가능 결합 수
- 2
- 무거운 원자 수
- 15
- 형식 전하
- 0
- 복잡도
- 246
실험 및 물리화학적 성질
물리화학적 성질
- 녹는점
- 230 ° · >230°
- 끓는 점
- 395.5 · 395.5±52.0 °C(Predicted)
- 밀도
- 1.63 · 1.63±0.1 g/cm3(Predicted)
- 저장 조건
- 2 · Sealed in dry,2-8°C
- 용해도
- 45 % · 45%(w/v) aq 2-하이드록시프로필--사이클로덱스트린: 1.4mg/mL 용액은 4℃에서 며칠 동안 보관할 수 있습니다.
- 산도 계수 (pKa)
- 9.26 · 9.26±0.50(Predicted)
- 물리적 상태
- 고체
- 색상
- 하얀색
안전 및 규제
GHS 분류
GHS Classification
Danger
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
P261, P262, P264, P270, P271, P280, P301+P316, P302+P352, P304+P340, P316, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
유해성 정보
독성 정보
안전 데이터
- wgk
- 3
- ridadr
- UN 2811 6.1/PG 1
- risk_code
- 23/24/25
- hazard_code
- T
- safety_code
- 22-36/37/39-45
화학 및 산업
약리 정보
ATC Code
S01EA03
S - Sensory organs
QS - Sensory organs
Mechanism of Action
Apraclonidine is a relatively selective alpha2 adrenergic receptor agonist that stimulates alpha1 receptors to a lesser extent. It has a peak ocular hypotensive effect occurring at two hours post-dosing. The exact mechanism of action is unknown, but fluorophotometric studies in animals and humans suggest that Apraclonidine has a dual mechanism of action by reducing aqueous humor production through the constriction of afferent ciliary process vessels, and increasing uveoscleral outflow.
FDA Pharmacological Classification
843CEN85DI
APRACLONIDINE
Mechanisms of Action [MoA] - Adrenergic alpha-Agonists
Established Pharmacologic Class [EPC] - alpha-Adrenergic Agonist
Apraclonidine is an alpha-Adrenergic Agonist. The mechanism of action of apraclonidine is as an Adrenergic alpha-Agonist.
APRACLONIDINE
Absorption, Distribution and Excretion
Topical use of apraclonidine ophthalmic solution leads to systemic absorption. Studies of apraclonidine (0.5% ophthalmic solution) dosed one drop three times a day in both eyes for 10 days in normal volunteers yielded mean peak and trough concentrations of 0.9 ng/mL and 0.5 ng/mL, respectively.
응용 분야
일반 설명In addition to its therapeutic use as an antihypertensiveagent, clonidine has been found to provide beneficialeffects in several other situations, including glaucoma,spasticity, migraine prophylaxis, opiate withdrawal syndrome,and anesthesia. This has prompted the developmentof analogs of clonidine for specific use in some of the mentionedareas. Two of such examples are apraclonidine andbrimonidine. Apraclonidine does not cross the BBB.However, brimonidine can cross the BBB and hence canproduce hypotension and sedation, although these CNSeffects are slight compared with those of clonidine. CNS effectsof these drugs are correlated well to their log P, pKa,and thus log D value. Both apraclonidine and brimonidineare selective α2-agonists with α1: α2 ratios of 30:1 and1,000:1, respectively. Brimonidine is a much more selectiveα2-agonist than clonidine or apraclonidine and is a firstlineagent for treating glaucoma. Apraclonidines’s primarymechanism of action may be related to a reduction of aqueousformation, whereas brimonidine lowers intraocularpressure by reducing aqueous humor production and increasinguveoscleral outflow. Apraclonidine is used specificallyto control elevations in intraocular pressure that canoccur during laser surgery on the eye. Another example istizanidine (Zanaflex), which finds use in treating spasticityassociated with multiple sclerosis or spinal cord injury. Bystimulating 2-adrenergic receptors, it is believed to decreasethe release of excitatory amino acid NTs from spinalcord interneurons.
상·하류 제품 정보
상류 원료
하류 제품
공급사14 곳
추가 설명
정의ChEBI: An imidazoline compound having a 4-amino-2,6-dichloroanilino group at the 2-position.
관련 반응
연결된 노트
불러오는 중…